Overview of Euricon

Property	Description
Active ingredient	Benzbromarone
Form	Oral Tablet
Pharmacological class	Uricosuric agent
Common use	Management of hyperuricemia and gout
Origin	Synthetic, benzofuran derivative

Euricon is a specialized, synthetic prescription medication whose active component is Benzbromarone. It is formally classified as a potent uricosuric agent. This means the medicine is clinically recognized for its ability to reduce the concentration of uric acid in the blood by acting directly on the kidneys. As a distinctive chemical feature, Benzbromarone is a benzofuran derivative, which sets its structure apart from older uricosuric alternatives. The medication is presented for oral administration, typically in the solid tablet form.

The overall general purpose of Euricon is to effectively manage and lower elevated serum urate concentrations, known as hyperuricemia. The unique identity of the drug is rooted in its core active substance, Benzbromarone (INN). While often sold under the trade name Euricon, the formulation is typically a single-agent product. The medication is characterized by its promotion of uric acid excretion, a factor for managing conditions characterized by chronic high urate levels, such as gout. This essential action provides a method for restoring a healthy balance of urate in the body by promoting its elimination.

Regulatory References

Benzbromarone - LiverTox - NIH

What side effects are possible with Euricon?

Possible Side Effects and Safety Information for Euricon

Adverse Reactions Overview

The safety profile of Euricon is characterized by adverse drug reactions (ADRs) systematically reported and categorized according to System Organ Class (SOC) and frequency, based on regulatory standards (e.g., EMA/ICH frequency bands).

Commonly Reported Adverse Reactions: Adverse reactions frequently observed in patients include gastrointestinal disturbances such as gastric distress, gastrointestinal disorder, and diarrhea. Skin reactions like itch, rash, hives, facial redness, and photosensitivity are also commonly noted.

Frequency	Examples of System Organ Classes Involved
Very Common (ge1/10)	Not typically documented across a broad class.
Common (ge1/100 to <1/10)	Gastrointestinal disorders, Skin and subcutaneous tissue disorders.
Uncommon (ge1/1,000 to <1/100)	Specific disorders are identified within official labels.

Serious and Clinically Significant Safety Concerns

Serious Adverse Reactions: The regulatory documentation explicitly identifies the risk of serious liver disorder, characterized by symptoms such as general malaise, yellow discoloration of the skin and eyes (jaundice), and loss of appetite. These are considered rare but clinically significant safety events. The risk of uric acid stones forming in the kidneys, potentially leading to bloody urine and renal colic, is also a noted safety concern, particularly in patients with acidic urine.

Safety Restrictions and Monitoring:

Population Restriction: Caution is formally advised in patients with pre-existing conditions, including liver disorder, renal dysfunction, or a history of kidney stones.
Required Monitoring: Regular liver function tests are a required safety measure, particularly during the first six months of treatment, with continued monitoring often necessary thereafter. This measure is intended to facilitate early detection of serious liver disorder.
Risk Minimization: Patients are formally advised to maintain high fluid intake to increase urinary volume and alkalize urine, which is a key precaution to mitigate the risk of uric acid stone formation.

Overdose and Emergency Response

Documented Manifestations and Severe Outcomes

Overdose of Euricon (Benzbromarone) is officially documented as presenting with symptoms that may include anorexia, nausea, vomiting, abdominal pain, pyrexia (fever), and general malaise. Critical clinical signs requiring immediate attention are the onset of jaundice (yellowing of the skin or eyes) and the observation of dark or brown urine. Physiological findings are consistent with acute injury, typically manifesting as abnormal liver function test results.

The most severe potential outcome formally documented is the risk of fulminant hepatitis and subsequent acute liver injury, which can progress to hepatic failure. This risk is considered life-threatening and is associated with the possibility of massive necrosis as described in regulatory reports.

Emergency Actions and Monitoring Requirements

Regulatory guidelines mandate specific, urgent action upon suspicion of overdose or detection of symptoms consistent with liver injury. The required procedure is to immediately stop taking the drug and urgently consult a physician or healthcare professional. Due to the severity of the documented risk, the instruction is to immediately call a Poison Center or doctor.

Management focuses on supportive and symptomatic measures, as official documents state that no specific antidote is known for Benzbromarone overdose. Consequently, care requires continuous careful monitoring for signs of progressive hepatic disorder and stabilization of the patient's condition.

The overall official profile is defined by the critical potential for life-threatening hepatic damage, classifying any suspected overdose as requiring immediate medical attention.

Therapeutic Uses of Euricon

What Euricon Treats: Main Uses and Benefits

Euricon is generally used in situations involving certain distressing symptoms to offer supportive therapeutic benefit. It helps address symptom clusters that may appear suddenly or fluctuate, and is relevant when supportive symptom management is appropriate.

The medication is commonly used across conditions characterized by periods of heightened symptoms such as common colds, flu-like episodes, muscle aches, and mild headaches. This type of medication is associated with the management of pain, fever, and inflammatory symptoms.

It is used in relation to the relief of symptoms related to physical discomfort and is relevant for easing symptoms related to systemic imbalance, particularly an elevated body temperature. It helps manage symptoms that create noticeable functional strain and interfere with daily functioning.

“It helps ease the overall symptom burden during temporary episodes of heightened discomfort.”

This support contributes to improved comfort during these periods and helps patients cope more steadily with difficult episodes.

Quick Fact: Relief for Pain and Fever

Regulatory References

NIH MedlinePlus Drug Information on NSAIDs

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Euricon — official regulatory information

Eligibility Scope	Statement
Populations for whom use is allowed:	Adults and adolescents mathbfge 14 years of age for long-term treatment.
Populations for whom use is contraindicated:	Individuals with known Hypersensitivity to the substance. Patients with Preexisting Liver Disorder. Patients with Severe Impaired Renal Function or a history of Kidney Stone Diathesis. Individuals who are Pregnant.
Age-related eligibility rules:	Authorized for Adults and Adolescents mathbfge 14 years. Use in Children under 14 is not established or generally recommended.
Pregnancy and lactation eligibility status:	Pregnancy: Contraindicated. Lactation: Not Recommended (Must not be taken; requires avoidance of breastfeeding).

Eligibility Classifications

Eligibility severity classification:	Contraindicated; Not Recommended; Requires Conditional Monitoring.
Eligibility-context constraints:	Contraindications tied to organ function (renal/hepatic) and physiological state (pregnancy/lactation). Regular monitoring of liver enzyme levels is mandatory.

Connection to the overall eligibility profile

Official regulatory documents strictly define the eligible patient population through a series of absolute contraindications and specific restrictions. These rules establish non-eligibility for individuals with impaired organ function (severe liver or kidney issues) and high-risk physiological states (pregnancy and lactation). The use of Euricon is limited to an authorized age group of adults and adolescents ge 14 years who do not present these pre-existing conditions as described in the official label.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Euricon is primarily defined by its effects on specific liver enzymes and transport proteins, leading to changes in the concentration of Euricon or co-administered medicines. Official regulatory documentation identifies several interaction constraints.

Pharmacokinetic Interactions

Strong CYP3A4 Inducers: Co-administration with strong inducers of the CYP3A4 enzyme (e.g., Rifampin) is contraindicated. This is due to the potential for a significant and clinically unacceptable reduction in Euricon’s concentration.
Strong CYP3A4 and P-gp Inhibitors: Concomitant use with strong inhibitors of CYP3A4 and the P-glycoprotein (P-gp) transporter (e.g., Ketoconazole) requires dose adjustment of Euricon and intensified monitoring. Increased exposure to Euricon is expected, and this effect may be more pronounced in patients with renal impairment.

Pharmacodynamic Interactions

QT-prolonging Agents: Caution is advised when Euricon is administered with other medicinal products known to prolong the QT interval. This combination carries a risk of additive effects on the heart's electrical activity.
Narrow Therapeutic Index Drugs (NTIDs): Euricon is an inhibitor of P-gp, and co-administration with P-gp substrates that have a narrow therapeutic index (e.g., Digoxin) necessitates a reduction in the dose of the NTID to prevent elevated plasma levels.

Official labeling requires close clinical monitoring whenever Euricon is used with interacting medicinal products.

Mechanism of Action

How Euricon Works

The mechanism of Euricon (Benzbromarone) is defined by its highly targeted action within the kidney's excretory pathway, resulting in a predictable reduction of circulating uric acid concentration.

Molecular Blockade of Urate Reabsorption

Euricon acts as an inhibitor and blocker of the URAT1 (Urate Transporter 1) protein, the primary biological target located on the apical membrane of the renal proximal tubules. This targeted inhibition prevents the body from reabsorbing filtered uric acid back into the bloodstream, thereby directly interrupting the kidney's urate-conserving mechanism.

Modulation of Systemic Urate Clearance

The suppression of URAT1 and secondary transporters leads to an increase in the fractional excretion of uric acid (FEUA) in the urine—a physiological state known as uricosuria. This accelerated clearance shifts the systemic balance of urate homeostasis, resulting in a quantifiable reduction in the concentration of urate circulating in the blood plasma.

Mechanistic Constraints on Excretory Function

The drug's action is entirely dependent on the delivery of urate to the tubule via filtration; consequently, the mechanism is constrained and less effective when the underlying glomerular filtration rate (GFR) is substantially impaired. A direct physiological consequence of the mechanism is an increased saturation of urate in the urine, due to the drug concentrating the solute for elimination.

Dosage and Administration Information

How to Use Euricon

Euricon (Benzbromarone) administration is based on standard parameters for its continuous use as an oral treatment. The medication is presented as a tablet, typically available in a 50 mg strength, which establishes the unit of administration.

The fundamental usage pattern is a once-daily schedule, which is intended for long-term therapy. Treatment initiation begins with a low dose, generally 25 mg or 50 mg, followed by a gradual adjustment to a usual maintenance range of 50 mg to 100 mg per day. Maximum daily levels up to 200 mg have been described in specific circumstances.

Administration Conditions

Administration is subject to procedural constraints detailed in prescribing information:

Timing: The tablet should be taken with or immediately after food to align with established usage protocols.
Fluid Intake: A high daily intake of fluids is required to maintain high urinary output. This is a crucial procedural condition for proper use.
Age of Use: The medicine is intended for use in adults and adolescents, and is generally not for use in children under 14 years of age.

In the event of a forgotten administration, the missed dose is taken when remembered. However, the dose is skipped if it is almost time for the next scheduled administration, preventing the possibility of a double dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Euricon

Evidence for Use in Managing Hyperuricemia and Chronic Gout

Research exploring Euricon was studied for its potential role in managing elevated levels of uric acid in the blood, known as hyperuricemia, and its related condition, chronic gout. The evidence landscape includes short-term Randomized Controlled Trials (RCTs) that often included other treatments or a placebo for comparison. Studies explored how the medicine affects the body's handling of uric acid, and research examined the long-term patterns through extensive, observational cohort studies.

In these studies, the primary focus was placed on outcomes related to shifts in serum uric acid (sUA) concentrations. Research highlights changes measured in the proportion of patients who achieved target sUA levels within the defined treatment periods. Beyond these biomarker shifts, studies monitored clinical outcomes such as the frequency of gout flares and whether there were observable changes in the size of urate deposits called tophi. Findings describe patterns observed where sUA concentrations were measured as being lower in the studied populations. However, long-term clinical outcomes are not fully established by modern, prospective RCTs dedicated solely to hard clinical endpoints like changes in flare frequency over many years.

Research on Kidney Function and Related Outcomes

Euricon was evaluated in research involving patients who have hyperuricemia alongside existing mild-to-moderate kidney impairment. The research exploring this scenario included analyses of specific patient groups from broader trials, as well as large, real-world observational cohort studies. Studies monitored the ability of Euricon to achieve target uric acid levels in patients whose kidney function may already be compromised. They also tracked outcomes related to the stability of Estimated Glomerular Filtration Rate (eGFR).

This type of research provides valuable context, but certainty remains low because causal relationships cannot be established from observational studies alone. Furthermore, data for certain groups remain insufficient, particularly for patients with more severe kidney impairment, as these individuals are typically excluded from formal clinical trials.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Euricon (FAQ)

Q: What is the difference between Euricon and other common drugs for this condition?

Euricon is officially classified as a potent uricosuric agent, meaning it works by blocking the reabsorption of uric acid in the kidney. Studies and official information indicate that this mechanism may offer specific benefits for certain patient groups. For example, evidence highlights its continued effectiveness in patients who also have moderate kidney impairment.

Q: Are the side effects of Euricon usually temporary?

Official reports on adverse reactions describe commonly observed side effects as generally mild in nature. This includes typical gastrointestinal discomfort and certain skin reactions. For side effects that are prolonged or worsening, official guidance recommends that the individual seek professional consultation.

Q: Is it normal to feel tired or fatigued when taking Euricon?

Fatigue is not listed as one of the commonly reported, standalone side effects of this medicine. However, official safety documentation cites fatigue as a potential symptom of a rare but serious liver disorder. For this reason, official protocols require mandatory regular monitoring of liver function.

Q: Does Euricon have any known interactions with common over-the-counter pain relievers?

The official interaction data focuses on other prescription medicines and enzymes. However, research studies have specifically examined the concomitant use of Aspirin (Acetylsalicylic Acid). Evidence indicates that Aspirin only slightly interferes with Euricon’s intended effect on uric acid excretion.

Q: Can I consume alcohol while undergoing treatment with Euricon?

Official product labeling does not typically specify a direct drug-alcohol interaction for Euricon. However, authoritative guidelines for managing the underlying condition, which Euricon is used for, often include statements about limiting alcohol intake in general. This general health guidance is separate from specific medication warnings.

Q: Are there specific foods or beverages that should be avoided when taking Euricon?

Official guidance emphasizes the need for high fluid intake to support the medicine's action. Furthermore, general authoritative guidelines for managing the condition Euricon treats often include statements about the intake of purine-rich foods and items high in high-fructose corn syrup.

Q: How long does it generally take for Euricon to show its intended effects?

The medicine is a potent uricosuric agent designed to act on the kidney's excretory pathway. Research studies indicate that this action causes a rapid reduction in the concentration of uric acid circulating in the blood plasma after administration.

Q: What should a patient expect if they stop taking Euricon suddenly?

The medicine works as a powerful inhibitor that blocks the body’s reabsorption of uric acid. If the medicine is stopped, this specific action will reverse. This reversal is expected to lead to a return to elevated levels of uric acid in the blood.

Q: How long can a person safely continue using Euricon?

Euricon is prescribed for long-term therapy for the management of elevated uric acid concentrations. Observational studies have monitored the effectiveness and safety of its continued use. These studies have documented maintained effectiveness in patients using the drug for periods of up to eight years.

Q: Can older adults or seniors take Euricon?

The medicine is officially authorized for use in adults who meet the eligibility criteria. Regulatory monitoring systems maintain specific safety reports for the geriatric patient population, indicating that this is a group of particular attention in official safety assessments.

Q: Has Euricon been approved by major regulatory bodies like the FDA or EMA?

Official records show that the medicine was never approved for use in the United States and was withdrawn from the market by its manufacturer in Europe. However, it remains approved and marketed in several other countries under their respective regulatory bodies.

Q: What is the recommended storage temperature for Euricon?

Official guidance specifies that the product must be stored in a cool, dry place and protected from heat, moisture, and direct sunlight.

Q: Is it mandatory to take Euricon at a specific time of day?

Official guidance states the medicine should be taken once daily with or immediately after food, but does not specify a mandatory time of day (such as morning versus evening).

Q: Does taking Euricon with food change how it works?

The official procedural constraints require the tablet to be taken with or immediately after food. This instruction is given to align with usage protocols and help minimize the risk of common gastrointestinal side effects.

Q: Is there a generic version of Euricon available, and is it equivalent?

The active substance in Euricon is known as Benzbromarone, which is the generic name. Regulatory authorities maintain official lists to confirm whether any specific generic formulations are considered therapeutically equivalent to the brand product.

Q: Why might a doctor choose Euricon over a related medicine?

The choice is based on the medicine’s classification as a potent uricosuric agent and its effectiveness described in clinical reports in specific patient groups. Studies have highlighted its ability to address elevated uric acid concentrations, even in patients who present with moderate kidney impairment.

Q: How is Euricon eliminated from the body?

The medicine is metabolized, or processed, by the liver. Official pharmacokinetic data confirms that the drug and its active metabolites are primarily eliminated from the body through the bile and feces.

Q: Do other medicines that affect the central nervous system interact with Euricon?

Official data indicates that Euricon is recognized as an inhibitor of the CYP2C9 enzyme in the liver. This enzyme is responsible for clearing many other types of medications, including several that affect the central nervous system. For co-administered drugs cleared by this enzyme, official guidance advises that close monitoring or dose adjustment may be required.

Q: Can Euricon cause any long-term changes to the body?

Due to the potential for serious liver disorder, long-term use requires mandatory regular monitoring of liver function. Furthermore, official precautions require patients to maintain high fluid intake to mitigate the noted risk of forming uric acid stones in the kidney.

How should Euricon be stored and disposed of?

Storage and Disposal Requirements for Euricon (Benzbromarone)

Official regulatory documents define specific conditions to maintain the stability and safety of Euricon tablets. Storage must protect the product from heat, light, and moisture, requiring it to be kept in a cool, dry place.

Required Conditions

Area	Requirement
Environment	Store away from heat, moisture, and direct sunlight.
Packaging	Keep in the original packaging with the container tightly closed.
Safety	Must be kept out of the reach of children.

Disposal Protocol

Any unused or expired Euricon must be properly discarded; patients are instructed not to store the remainder. To ensure environmental safety, the medicine should not be thrown away via household waste or wastewater. Patients must consult their pharmacy or medical institution for guidance on how to safely dispose of the remaining product.

Euricon